Sugi Predict

Sugi Predict / Compounds / SCHEMBL1248419

SCHEMBL1248419

SCHEMBL1248419

Nc1nc(Nc2ccccc2)sc1C(=O)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNA2 P20248 10/20 1.00
▸ CDK2 P24941 10/20 1.00
▸ CDK5 Q00535 5/20 1.00
▸ CDK5R1 Q15078 5/20 1.00
▸ MAPT P10636 4/20 1.00
▸ NPC1 O15118 4/20 1.00
▸ RAB9A P51151 3/20 1.00
▸ GSK3A P49840 1/20 1.00
▸ GSK3B P49841 1/20 1.00
▸ MAPK14 Q16539 1/20 1.00
▸ TDP1 Q9NUW8 1/20 1.00
▸ MEN1 O00255 4/20 0.79
▸ KMT2A Q03164 4/20 0.79
▸ LMNA P02545 1/20 0.79
▸ ALDH1A1 P00352 1/20 0.70
▸ POLB P06746 1/20 0.70
▸ ADORA2B P29275 1/20 0.68
▸ CCNT1 O60563 1/20 0.67
▸ CDK4 P11802 1/20 0.67
▸ CCND1 P24385 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724765 0.93 CCNA2 (0.87) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL25609626 0.92 CCNA2 (0.85) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL26459438 0.92 CDK5 (0.85) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL1250519 0.92 CCNA2 (0.85) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL4473692 0.92 CCNA2 (0.85) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL4391125 0.92 CDK5 (0.85) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL20142474 0.91 CCNA2 (0.82) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL4404095 0.91 CCNA2 (0.82) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL7756168 0.91 CCNA2 (1.00) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL20142253 0.91 CCNA2 (0.82) CCNA2CDK2CDK5CDK5R1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018089902-A1 DIAMINOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2018-05-17 — — WO claimed
US-20090312390-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA ALCON, INC. (CH) 2009-12-17 — — US claimed
CN-101380319-A Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma ALCON INC (CH) 2009-03-11 — — CN claimed
EP-1430120-A4 INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA ALCON INC (CH) 2007-06-20 — — EP claimed
CN-1561393-A Inhibitors of glycogen synthase kinase-3 (GSK-3) for the treatment of glaucoma ALCON INC (CH) 2005-01-05 — — CN claimed
US-20040186159-A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma NOVARTIS AG (CH) 2004-09-23 — — US claimed
EP-1430120-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA Alcon, Inc. (CH) 2004-06-23 — — EP claimed
WO-2003027275-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA ALCON, INC. (CH) 2003-04-03 — — WO claimed
CN-115697980-B Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2025-03-21 — — CN disclosed
EP-4139286-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 — — EP disclosed
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 — — US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
CN-1561393-A Inhibitors of glycogen synthase kinase-3 (GSK-3) for the treatment of glaucoma ALCON INC (CH) 2005-01-05 — — CN disclosed
US-20040186159-A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma NOVARTIS AG (CH) 2004-09-23 — — US disclosed
EP-1430120-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA Alcon, Inc. (CH) 2004-06-23 — — EP disclosed
WO-2003027275-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA ALCON, INC. (CH) 2003-04-03 — — WO disclosed
US-20010039275-A1 Use of 2,4-diaminothiazole derivatives NOVO NORDISK A/S (DK) 2001-11-08 — — US disclosed
WO-2001056567-A1 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS NOVO NORDISK A/S (DK) 2001-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186159-A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma GSK3B, GSK3A, GSKIP CCNA2 4260/4885CDK2 1208/4885CDK5 367/4885
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG CCNA2 851/4885CDK2 239/4885CDK5 591/4885
US-20090312390-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA GSK3B, GSK3A, GSKIP CCNA2 4260/4885CDK2 1208/4885CDK5 367/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG CCNA2 851/4885CDK2 239/4885CDK5 591/4885
US-20010039275-A1 Use of 2,4-diaminothiazole derivatives GSK3A, GSK3B, GSKIP CCNA2 3738/4885CDK2 566/4885CDK5 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.